Neuroprotection in acute stroke: Is there still hope?

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Efficacious treatment of acute stroke is a major challenge in modern medicine. Therapeutic neuroprotection acting towards minimization of ischemic neuronal injury in penumbral tissue in the regions of reduced cerebral blood flow seems to be an appealing concept in the treatment of acute stroke and brain trauma. The 'ischemic cascade', a complex mechanism of metabolic events initiated by brain ischemia, offers many pathways by which the neuroprotective agents may act. Time to treatment remains a major limiting factor for many potential neuroprotective agents. Although the exact therapeutic window is not known, evidence from many animal models and clinical research suggest that neuroprotective therapy can only be efficacious if administered very early after the onset of ischemia. Various neuroprotective agents have been tested in many clinical stroke trials during the past 20 years. Large phase III clinical trials of several classes of neuroprotectants (mainly NMDA receptor antagonists, free radical scavengers, and calcium channel blockers) have recently failed to demonstrate efficacy of neuroprotection. After initial disappointment, the active research continues and some new exciting neuroprotective models emerge on the horizon.

Original languageEnglish
Pages (from-to)45-49
Number of pages5
JournalActa Clinica Croatica
Volume41
Issue number1
StatePublished - Apr 25 2002
Externally publishedYes

Fingerprint

Neuroprotective Agents
Stroke
Cerebrovascular Circulation
Phase III Clinical Trials
Free Radical Scavengers
Modern 1601-history
Calcium Channel Blockers
N-Methyl-D-Aspartate Receptors
Brain Ischemia
Research
Therapeutics
Ischemia
Animal Models
Clinical Trials
Neuroprotection
Wounds and Injuries

Keywords

  • Cerebrovascular accident, drug therapy
  • Clinical trial
  • Neuroprotective agents
  • Treatment outcome

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Neuroprotection in acute stroke : Is there still hope? / Rundek, Tatjana; Sacco, Ralph L; Demarin, Vida.

In: Acta Clinica Croatica, Vol. 41, No. 1, 25.04.2002, p. 45-49.

Research output: Contribution to journalArticle

@article{1b30c500232c4593bddfd26aeadeb8e6,
title = "Neuroprotection in acute stroke: Is there still hope?",
abstract = "Efficacious treatment of acute stroke is a major challenge in modern medicine. Therapeutic neuroprotection acting towards minimization of ischemic neuronal injury in penumbral tissue in the regions of reduced cerebral blood flow seems to be an appealing concept in the treatment of acute stroke and brain trauma. The 'ischemic cascade', a complex mechanism of metabolic events initiated by brain ischemia, offers many pathways by which the neuroprotective agents may act. Time to treatment remains a major limiting factor for many potential neuroprotective agents. Although the exact therapeutic window is not known, evidence from many animal models and clinical research suggest that neuroprotective therapy can only be efficacious if administered very early after the onset of ischemia. Various neuroprotective agents have been tested in many clinical stroke trials during the past 20 years. Large phase III clinical trials of several classes of neuroprotectants (mainly NMDA receptor antagonists, free radical scavengers, and calcium channel blockers) have recently failed to demonstrate efficacy of neuroprotection. After initial disappointment, the active research continues and some new exciting neuroprotective models emerge on the horizon.",
keywords = "Cerebrovascular accident, drug therapy, Clinical trial, Neuroprotective agents, Treatment outcome",
author = "Tatjana Rundek and Sacco, {Ralph L} and Vida Demarin",
year = "2002",
month = "4",
day = "25",
language = "English",
volume = "41",
pages = "45--49",
journal = "Acta Clinica Croatica",
issn = "0353-9466",
publisher = "Klinicka Bolnica Sestre Milosrdnice",
number = "1",

}

TY - JOUR

T1 - Neuroprotection in acute stroke

T2 - Is there still hope?

AU - Rundek, Tatjana

AU - Sacco, Ralph L

AU - Demarin, Vida

PY - 2002/4/25

Y1 - 2002/4/25

N2 - Efficacious treatment of acute stroke is a major challenge in modern medicine. Therapeutic neuroprotection acting towards minimization of ischemic neuronal injury in penumbral tissue in the regions of reduced cerebral blood flow seems to be an appealing concept in the treatment of acute stroke and brain trauma. The 'ischemic cascade', a complex mechanism of metabolic events initiated by brain ischemia, offers many pathways by which the neuroprotective agents may act. Time to treatment remains a major limiting factor for many potential neuroprotective agents. Although the exact therapeutic window is not known, evidence from many animal models and clinical research suggest that neuroprotective therapy can only be efficacious if administered very early after the onset of ischemia. Various neuroprotective agents have been tested in many clinical stroke trials during the past 20 years. Large phase III clinical trials of several classes of neuroprotectants (mainly NMDA receptor antagonists, free radical scavengers, and calcium channel blockers) have recently failed to demonstrate efficacy of neuroprotection. After initial disappointment, the active research continues and some new exciting neuroprotective models emerge on the horizon.

AB - Efficacious treatment of acute stroke is a major challenge in modern medicine. Therapeutic neuroprotection acting towards minimization of ischemic neuronal injury in penumbral tissue in the regions of reduced cerebral blood flow seems to be an appealing concept in the treatment of acute stroke and brain trauma. The 'ischemic cascade', a complex mechanism of metabolic events initiated by brain ischemia, offers many pathways by which the neuroprotective agents may act. Time to treatment remains a major limiting factor for many potential neuroprotective agents. Although the exact therapeutic window is not known, evidence from many animal models and clinical research suggest that neuroprotective therapy can only be efficacious if administered very early after the onset of ischemia. Various neuroprotective agents have been tested in many clinical stroke trials during the past 20 years. Large phase III clinical trials of several classes of neuroprotectants (mainly NMDA receptor antagonists, free radical scavengers, and calcium channel blockers) have recently failed to demonstrate efficacy of neuroprotection. After initial disappointment, the active research continues and some new exciting neuroprotective models emerge on the horizon.

KW - Cerebrovascular accident, drug therapy

KW - Clinical trial

KW - Neuroprotective agents

KW - Treatment outcome

UR - http://www.scopus.com/inward/record.url?scp=0036229179&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036229179&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0036229179

VL - 41

SP - 45

EP - 49

JO - Acta Clinica Croatica

JF - Acta Clinica Croatica

SN - 0353-9466

IS - 1

ER -